332 related articles for article (PubMed ID: 24568188)
1. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
Lee D; Porter J; Gladwell D; Brereton N; Nielsen SK
J Med Econ; 2014 Apr; 17(4):233-47. PubMed ID: 24568188
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Lu L; Peters J; Roome C; Stein K
BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
5. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
6. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
7. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
[TBL] [Abstract][Full Text] [Related]
8. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
[TBL] [Abstract][Full Text] [Related]
9. Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Whyte S; Gomersall T; Ren S; Wong R; Chambers D; Tappenden P
Pharmacoeconomics; 2017 Jul; 35(7):717-726. PubMed ID: 27943135
[TBL] [Abstract][Full Text] [Related]
10. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
[TBL] [Abstract][Full Text] [Related]
11. Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis.
Yan J; Li C; Zhang X; Cheng L; Ding R; Zhang L
Front Public Health; 2022; 10():942800. PubMed ID: 35923949
[TBL] [Abstract][Full Text] [Related]
12. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
Schröder FH; Tombal B; Miller K; Boccon-Gibod L; Shore ND; Crawford ED; Moul J; Olesen TK; Persson BE
BJU Int; 2010 Jul; 106(2):182-7. PubMed ID: 19912212
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Van Poppel H; Klotz L
Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
[TBL] [Abstract][Full Text] [Related]
14. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.
Raddin RS; Walko CM; Whang YE
Anticancer Drugs; 2011 Mar; 22(3):299-302. PubMed ID: 21360851
[TBL] [Abstract][Full Text] [Related]
15. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
16. Quality of life improvement in patients treated with degarelix versus leuprorelin for advanced prostate cancer.
Lee D; Nielsen SK; van Keep M; Andersson F; Greene D
J Urol; 2015 Mar; 193(3):839-46. PubMed ID: 25264336
[TBL] [Abstract][Full Text] [Related]
17. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
Boccon-Gibod L; Iversen P; Persson BE
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
[TBL] [Abstract][Full Text] [Related]
18. Utility of LHRH antagonists for advanced prostate cancer.
Moul JW
Can J Urol; 2014 Apr; 21(2 Supp 1):22-7. PubMed ID: 24775720
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
Iannazzo S; Pradelli L; Carsi M; Perachino M
Value Health; 2011 Jan; 14(1):80-9. PubMed ID: 21211489
[TBL] [Abstract][Full Text] [Related]
20. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
